The quest for selective nox inhibitors and therapeutics: Challenges, triumphs and pitfalls

Antioxidants and Redox Signaling

Volumn 20, Issue 17, 2014, Pages 2741-2754

  Cifuentes Pagano, Eugenia ^a   Meijles, Daniel N ^a   Pagano, Patrick J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOCYNIN; CELASTROL; CYTOCHROME B558; DIPHENYLIODONIUM SALT; EBSELEN; NALOXONE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE INHIBITOR; PEROXIDASE; PROTEIN P22; PROTEIN P40; PROTEIN P47; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; SCAVENGER; SUPEROXIDE; TRIPHENYLMETHANE DERIVATIVE; UNCLASSIFIED DRUG; XANTHINE OXIDASE; ANTIOXIDANT; ENZYME INHIBITOR; ISOPROTEIN;

CELL FREE SYSTEM; CELL MEMBRANE; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART FAILURE; HUMAN; MOLECULAR LIBRARY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; NADPH OXIDASE; OXIDATIVE STRESS; PROTEIN ISOFORMS; REACTIVE OXYGEN SPECIES;

EID: 84901054437     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5620     Document Type: Review

References (180)

1. Abais JM, Zhang C, Xia M, Liu Q, Gehr TW, Boini KM, and Li PL. NADPH Oxidase-Mediated Triggering of Inflammasome in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid Redox Signal 18: 1537-1548, 2013
2. Al Ghouleh I, Khoo NK, Knaus UG, Griendling KK, Touyz RM, Thannickal VJ, Barchowsky A, Nauseef WM, Kelley EE, Bauer PM, Darley-Usmar V, Shiva S, Cifuentes-Pagano E, Freeman BA, Gladwin MT, and Pagano PJ. Oxidases and peroxidases in cardiovascular and lung disease: New concepts in reactive oxygen species signaling. Free Radic Biol Med 51: 1271-1288, 2011
3. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, and Ghigo D. Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 9: 686-696, 2008
4. Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, and Caldwell RB. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167: 599-607, 2005
5. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, Ho H, Wingler K, and Schmidt HH. The NOX toolbox: Validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 69: 2327-2343, 2012
6. Amanso AM and Griendling KK. Differential roles of NADPH oxidases in vascular physiology and pathophysiology. Front Biosci (Schol Ed) 4: 1044-1064, 2012
7. Ameziane-El-Hassani R, Morand S, Boucher JL, Frapart YM, Apostolou D, Agnandji D, Gnidehou S, Ohayon R, Noel-Hudson MS, Francon J, Lalaoui K, Virion A, and Dupuy C. Dual oxidase-2 has an intrinsic Ca2 +-dependent H2O2-generating activity. J Biol Chem 280: 30046-30054, 2005
8. Anderson D and Phillips BJ. Comparative in vitro and in vivo effects of antioxidants. Food Chem Toxicol 37: 1015-1025, 1999
9. Ansari MA and Scheff SW. NADPH-oxidase activation and cognition in Alzheimer disease progression. Free Radic Biol Med 51: 171-178, 2011
10. Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, Molango S, Heitz F, Merlot C, Szyndralewiez C, Page P, and Brenner DA. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56: 2316-2327, 2012
11. Banfi B, Molnar G, Maturana A, Steger K, Hegedus B, Demaurex N, and Krause KH. A Ca(2 + )-Activated NADPH oxidase in testis, spleen, and lymph nodes. J Biol Chem 276: 37594-37601, 2001
12. Bedard K, Jaquet V, and Krause KH. NOX5: From basic biology to signaling and disease. Free Radic Biol Med 52: 725-734, 2012
13. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 87: 245-313, 2007
14. Bendall JK, Cave AC, Heymes C, Gall N, and Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296, 2002
15. Bhandarkar SS, Jaconi M, Fried LE, Bonner MY, Lefkove B, Govindarajan B, Perry BN, Parhar R, Mackelfresh J, Sohn A, Stouffs M, Knaus U, Yancopoulos G, Reiss Y, Benest AV, Augustin HG, and Arbiser JL. Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest 119: 2359-2365, 2009
16. Borbely G, Szabadkai I, Horvath Z, Marko P, Varga Z, Breza N, Baska F, Vantus T, Huszar M, Geiszt M, Hunyady L, Buday L, Orfi L, and Keri G. Small-molecule inhibitors of NADPH oxidase 4. J Med Chem 53: 6758-6762, 2010
17. Bosco EE, Kumar S, Marchioni F, Biesiada J, Kordos M, Szczur K, Meller J, Seibel W, Mizrahi A, Pick E, Filippi MD, and Zheng Y. Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. Chem Biol 19: 228-242, 2012
18. Brieger K, Schiavone S, Miller FJ Jr., and Krause KH. Reactive oxygen species: From health to disease. Swiss Med Wkly 142: W13659, 2012
19. Brinker AM, Ma J, Lipsky PE, and Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68: 732-766, 2007
20. Brown DI and Griendling KK. Nox proteins in signal transduction. Free Radic Biol Med 47: 1239-1253, 2009
21. Cangemi R, Celestini A, Del Ben M, Pignatelli P, Carnevale R, Proietti M, Calabrese CM, Basili S, and Violi F. Role of platelets in NOX2 activation mediated by TNFalpha in heart failure. Intern Emerg Med 2012 [Epub ahead of print]; DOI: 10.1007/s11739-012-0837-2
22. Carnesecchi S, Pache JC, and Barazzone-Argiroffo C. NOX enzymes: Potential target for the treatment of acute lung injury. Cell Mol Life Sci 69: 2373-2385, 2012
23. Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, Wierzbicki M, Verbeuren TJ, and Cohen RA. S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 21: 1577-1584, 2001
24. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, and Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285: R117-R124, 2003
25. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269: 131-140, 2001
26. Cheng G, Ritsick D, and Lambeth JD. Nox3 regulation by NOXO1, p47phox, and p67phox. J Biol Chem 279: 34250-34255, 2004
27. Choi DH, Cristovao AC, Guhathakurta S, Lee J, Joh TH, Beal MF, and Kim YS. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal 16: 1033-1045, 2012
28. Cifuentes ME and Pagano PJ. Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 15: 179-186, 2006
29. Cifuentes-Pagano E, Csanyi G, and Pagano PJ. NADPH oxidase inhibitors: A decade of discovery from Nox2ds to HTS. Cell Mol Life Sci 69: 2315-2325, 2012
30. Cifuentes-Pagano E, Saha J, Csanyi G, Al Ghouleh I, Sahoo S, Rodriguez A, Wipf P, Pagano PJ, and Skoda EM. Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors. MedChemComm 4: 1085-1092, 2013
31. Cross AR. Inhibitors of the leukocyte superoxide generating oxidase: Mechanisms of action and methods for their elucidation. Free Radic Biol Med 8: 71-93, 1990
32. Cross AR and Jones OT. The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labelling of a component polypeptide of the oxidase. Biochem J 237: 111-116, 1986
33. Cross AR and Segal AW. The NADPH oxidase of professional phagocytes-prototype of the NOX electron transport chain systems. Biochim Biophys Acta 1657: 1-22, 2004
34. Csanyi G and Pagano PJ. Strategies aimed at Nox4 oxidase inhibition employing peptides from Nox4 B-loop and Cterminus and p22 (phox) N-Terminus: An elusive target. Int J Hypertens 2013: 842827, 2013
35. Csanyi G, Cifuentes-Pagano E, Al Ghouleh I, Ranayhossaini DJ, Egana L, Lopes LR, Jackson HM, Kelley EE, and Pagano PJ. Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic Biol Med 51: 1116-1125, 2011
36. Csanyi G, Taylor WR, and Pagano PJ. NOX and inflammation in the vascular adventitia. Free Radic Biol Med 47: 1254-1266, 2009
37. Dahan I and Pick E. Strategies for identifying synthetic peptides to act as inhibitors of NADPH oxidases, or "all that you did and did not want to know about Nox inhibitory peptides". Cell Mol Life Sci 69: 2283-2305, 2012
38. Dahan I, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, and Pick E. Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by "peptide walking". J Biol Chem 277: 8421-8432, 2002
39. Dahan I, Molshanski-Mor S, and Pick E. Inhibition of NADPH oxidase activation by peptides mapping within the dehydrogenase region of Nox2-A "peptide walking" study. J Leukoc Biol 91: 501-515, 2012
40. Datla SR and Griendling KK. Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension 56: 325-330, 2010
41. DeLeo FR, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, and Quinn MT. Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries. Proc Natl Acad Sci USA 92: 7110-7114, 1995
42. Dennis KE, Aschner JL, Milatovic D, Schmidt JW, Aschner M, Kaplowitz MR, Zhang Y, and Fike CD. NADPH oxidases and reactive oxygen species at different stages of chronic hypoxia-induced pulmonary hypertension in newborn piglets. Am J Physiol Lung Cell Mol Physiol 297: L596-L607, 2009
43. Diatchuk V, Lotan O, Koshkin V, Wikstroem P, and Pick E. Inhibition of NADPH oxidase activation by 4-(2-Aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 272: 13292-13301, 1997
44. Doroshow JH, Gaur S, Markel S, Lu J, van Balgooy J, Synold TW, Xi B, Wu X, and Juhasz A. Effects of iodoniumclass flavin dehydrogenase inhibitors on growth, reactive oxygen production, cell cycle progression, NADPH oxidase 1 levels, and gene expression in human colon cancer cells and xenografts. Free Radic Biol Med 57: 162-175, 2013
45. Dourron HM, Jacobson GM, Park JL, Liu J, Reddy DJ, Scheel ML, and Pagano PJ. Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am J Physiol Heart Circ Physiol 288: H946-H953, 2005
46. Doussiere J and Vignais PV. Diphenylene iodonium as an inhibitor of the NADPH oxidase complex of bovine neutrophils. Factors controlling the inhibitory potency of diphenylene iodonium in a cell-free system of oxidase activation. Eur J Biochem 208: 61-71, 1992
47. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002
48. Drummond GR, Selemidis S, Griendling KK, and Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471, 2011
49. Duerrschmidt N, Stielow C, Muller G, Pagano PJ, and Morawietz H. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells. J Physiol 576: 557-567, 2006
50. El-Benna J, Dang PM, and Perianin A. Towards specific NADPH oxidase inhibition by small synthetic peptides. Cell Mol Life Sci 69: 2307-2314, 2012
51. Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, Fujisawa Y, Lu XM, Fu H, Du J, Ohmori K, Hosomi N, Kimura S, Kiyomoto H, and Nishiyama A. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J Hypertens 27: 1855-1862, 2009
52. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 194: 7-15, 2011
53. Fujii A, Nakano D, Katsuragi M, Ohkita M, Takaoka M, Ohno Y, and Matsumura Y. Role of gp91phox-containing NADPH oxidase in the deoxycorticosterone acetate-saltinduced hypertension. Eur J Pharmacol 552: 131-134, 2006
54. Fulton DJ. Nox5 and the regulation of cellular function. Antioxid Redox Signal 11: 2443-2452, 2009
55. Furst R, Brueckl C, Kuebler WM, Zahler S, Krotz F, Gorlach A, Vollmar AM, and Kiemer AK. Atrial natriuretic peptide induces mitogen-Activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/ Nox2-Activation. Circ Res 96: 43-53, 2005
56. Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, and Page P. Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine,-pyrazine and-oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorg Med Chem 19: 6989-6999, 2011
57. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Ruegg C, Krause KH, and Imhof B. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6: E14665, 2011
58. Gatto GJ Jr., Ao Z, Kearse MG, Zhou M, Morales CR, Daniels E, Bradley BT, Goserud MT, Goodman KB, Douglas SA, Harpel MR, and Johns DG. NADPH oxidasedependent and-independent mechanisms of reported inhibitors of reactive oxygen generation. J Enzyme Inhib Med Chem 28: 95-104, 2013
59. Geiszt M. NADPH oxidases: New kids on the block. Cardiovasc Res 71: 289-299, 2006
60. Gianni D, Taulet N, Zhang H, DerMardirossian C, Kister J, Martinez L, Roush WR, Brown SJ, Bokoch GM, and Rosen H. A novel and specific NADPH oxidase-1 (Nox1) smallmolecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem Biol 5: 981-993, 2010
61. Giannoni E and Chiarugi P. Redox circuitries driving Src regulation. Antioxid Redox Signal 20: 2011-2025, 2014
62. Gorin Y. Nox4 as a potential therapeutic target for treatment of uremic toxicity associated to chronic kidney disease. Kidney Int 83: 541-543, 2013
63. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, De Haan JB, Koulis C, El-Osta A, and rews KL, Chin-Dusting JP, Touyz RM, Wingler K, Cooper ME, Schmidt HH, and Jandeleit-Dahm KA. Nox1 plays a key role in diabetes accelerated atherosclerosis. Circulation 127: 1888-1902, 2013
64. Green DE, Murphy TC, Kang BY, Kleinhenz JM, Szyndralewiez C, Page P, Sutliff RL, and Hart CM. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol 47: 718-726, 2012
65. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994
66. Groemping Y and Rittinger K. Activation and assembly of the NADPH oxidase: A structural perspective. Biochem J 386: 401-416, 2005
67. Groemping Y, Lapouge K, Smerdon SJ, and Rittinger K. Molecular basis of phosphorylation-induced activation of the NADPH oxidase. Cell 113: 343-355, 2003
68. Group TA-TBCCPS. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330: 1029-1035, 1994
69. Hansen J, Palmfeldt J, Vang S, Corydon TJ, Gregersen N, and Bross P. Quantitative proteomics reveals cellular targets of celastrol. PLoS One 6: E26634, 2011
70. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, and Hussain SN. Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J 19: 1728-1730, 2005
71. Hecker L, Cheng J, and Thannickal VJ. Targeting NOX enzymes in pulmonary fibrosis. Cell Mol Life Sci 69: 2365-2371, 2012
72. Heron M. Deaths: Leading causes for 2008. Natl Vital Stat Rep 60: 1-94, 2012
73. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, and Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211-217, 2008
74. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, Cohen RA, and Zang M. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-Activated protein kinase. J Biol Chem 283: 20015-20026, 2008
75. Iwai M, Kanno H, Inaba S, Senba I, Sone H, Nakaoka H, and Horiuchi M. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice. Am J Hypertens 24: 169-174, 2011
76. Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, and rzejewski T, and Pagano PJ. Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res 92: 637-643, 2003
77. Jaquet V, Marcoux J, Forest E, Leidal KG, McCormick S, Westermaier Y, Perozzo R, Plastre O, Fioraso-Cartier L, Diebold B, Scapozza L, Nauseef WM, Fieschi F, Krause KH, and Bedard K. NOX NADPH oxidase isoforms are inhibited by celastrol with a dual mode of action. Br J Pharmacol 164: 507-520, 2011
78. Jaquet V, Scapozza L, Clark R, Krause KH, and Lambeth JD. Small molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 11: 2535-2552, 2009
79. Jiang J, Kang H, Song X, Huang S, Li S, and Xu J. A model of interaction between nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and apocynin analogues by docking method. Int J Mol Sci 14: 807-817, 2013
80. Jiang JX, Chen X, Serizawa N, Szyndralewiez C, Page P, Schroder K, Brandes RP, Devaraj S, and Torok NJ. Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 53: 289-296, 2012
81. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, and Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109: 1795-1801, 2004
82. Kahles T, Luedike P, Endres M, Galla HJ, Steinmetz H, Busse R, Neumann-Haefelin T, and Brandes RP. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38: 3000-3006, 2007
83. Kay CD, Kris-Etherton PM, and West SG. Effects of antioxidant-rich foods on vascular reactivity: Review of the clinical evidence. Curr Atheroscler Rep 8: 510-522, 2006
84. Kilpatrick LE, Sun S, Li H, Vary TC, and Korchak HM. Regulation of TNF-induced oxygen radical production in human neutrophils: Role of delta-PKC. J Leukoc Biol 87: 153-164, 2010
85. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, and Thapa P. NADPH oxidase inhibitors: A patent review. Expert Opin Ther Pat 21: 1147-1158, 2011
86. Kim JH, Lee JO, Lee SK, Kim N, You GY, Moon JW, Sha J, Kim SJ, Park SH, and Kim HS. Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-Activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. Cell Signal 25: 805-813, 2013
87. Klaunig JE, Kamendulis LM, and Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 38: 96-109, 2010
88. Kleikers PW, Wingler K, Hermans JJ, Diebold I, Altenhofer S, Radermacher KA, Janssen B, Gorlach A, and Schmidt HH. NADPH oxidases as a source of oxidative stress and molecular target in ischemia/reperfusion injury. J Mol Med (Berl) 90: 1391-1406, 2012
89. Kleniewska P, Piechota A, Skibska B, and Goraca A. The NADPH oxidase family and its inhibitors. Arch Immunol Ther Exp (Warsz) 60: 277-294, 2012
90. Kofler PA, Pircher H, von Grafenstein S, Diener T, Holl M, Liedl KR, Siems K, and Jansen-Durr P. Characterisation of nox4 inhibitors from edible plants. Planta Med 79: 244-252, 2013
91. Koziel R, Pircher H, Kratochwil M, Lener B, Hermann M, Dencher NA, and Jansen-Durr P. Mitochondrial respiratory chain complex I is inactivated by NADPH oxidase Nox4. Biochem J 452: 231-239, 2013
92. Krause KH. Tissue distribution and putative physiological function of NOX family NADPH oxidases. Jpn J Infect Dis 57: S28-S29, 2004
93. Krause KH and Bedard K. NOX enzymes in immuno-inflammatory pathologies. Semin Immunopathol 30: 193-194, 2008
94. Krö ller-Schön S, Steven S, Kossmann S, Scholz A, Daub S, Oelze M, Xia N, Hausding M, Mikhed Y, Zinssius E, Mader M, Stamm P, Treiber N, Scharffetter-Kochanek K, Li H, Schulz E, Wenzel P, Mü nzel T, and Daiber A. Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal 20: 247-266, 2014
95. Krotz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, Duyster J, Cohen CD, Schuhmann C, Klauss V, Pohl U, Stempfle HU, and Sohn HY. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 49: 201-208, 2007
96. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, and Pohl U. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100: 917-924, 2002
97. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, and Page P. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 53: 7715-7730, 2010
98. Lambeth JD, Krause KH, and Clark RA. NOX enzymes as novel targets for drug development. Semin Immunopathol 30: 339-363, 2008
99. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, Jo H, Holland SM, and Harrison DG. Role of p47 phox in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511-515, 2002
100. Lange S, Heger J, Euler G, Wartenberg M, Piper HM, and Sauer H. Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species. Cardiovasc Res 81: 159-168, 2009
101. Lassegue B, San Martin A, and Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 110: 1364-1390, 2012
102. Lee I, Dodia C, Chatterjee S, Zagorski J, Mesaros C, Blair IA, Feinstein SI, Jain M, and Fisher AB. A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung. J Pharmacol Exp Ther 345: 284-296, 2013
103. Leto TL, Morand S, Hurt D, and Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 11: 2607-2619, 2009
104. Li JM, Newburger PE, Gounis MJ, Dargon P, Zhang X, and Messina LM. Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model. Gene Ther 17: 1279-1287, 2010
105. Liu J, Ormsby A, Oja-Tebbe N, and Pagano PJ. Gene transfer of NAD(P)H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ Res 95: 587-594, 2004
106. Liu J, Yang F, Yang XP, Jankowski M, and Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 23: 776-782, 2003
107. Liu Y, Qin L, Wilson BC, An L, Hong JS, and Liu B. Inhibition by naloxone stereoisomers of beta-Amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 302: 1212-1219, 2002
108. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR, Hope, and Investigators H-TT. Effects of long-Term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 293: 1338-1347, 2005
109. Lopes NHM, Vasudevan SS, Gregg D, Selvakumar B, Pagano PJ, Kovacic H, and Goldschmidt-Clermont PJ. Racdependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. Circ Res 91: 798-805, 2002
110. Loukogeorgakis SP, van Den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee B, De Groot E, MacAllister RJ, Kuijpers TW, and Deanfield JE. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 121: 2310-2316, 2010
111. Martin A, Perez-Giron JV, Hernanz R, Palacios R, Briones AM, Fortuno A, Zalba G, Salaices M, and Alonso MJ. Peroxisome proliferator-Activated receptor-gamma activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress. J Hypertens 30: 315-326, 2012
112. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, Alvarez Y, Aguado A, Perez-Giron JV, Garcia-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM, and Salaices M. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51-65, 2013
113. Massenet C, Chenavas S, Cohen-Addad C, Dagher MC, Brandolin G, Pebay-Peyroula E, and Fieschi F. Effects of p47phox C terminus phosphorylations on binding interactions with p40phox and p67phox. Structural and functional comparison of p40phox and p67phox SH3 domains. J Biol Chem 280: 13752-13761, 2005
114. Mohazzab KM, Kaminski PM, and Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 266: H2568-H2572, 1994
115. Montezano AC and Touyz RM. Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: A basic science update for the clinician. Can J Cardiol 28: 288-295, 2012
116. Morachis JM, Mahmoud EA, and Almutairi A. Physical and chemical strategies for therapeutic delivery by using polymeric nanoparticles. Pharmacol Rev 64: 505-519, 2012
117. Morozov I, Lotan O, Joseph G, Gorzalczany Y, and Pick E. Mapping of functional domains in p47 phox involved in the activation of NADPH oxidase by "peptide walking". J Biol Chem 273: 15435-15444, 1998
118. Musset B, Clark RA, DeCoursey TE, Petheo GL, Geiszt M, Chen Y, Cornell JE, Eddy CA, Brzyski RG, and El Jamali A. NOX5 in human spermatozoa: Expression, function, and regulation. J Biol Chem 287: 9376-9388, 2012
119. Niethammer P, Grabher C, Look AT, and Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 459: 996-999, 2009
120. Niu XL, Madamanchi NR, Vendrov AE, Tchivilev I, Rojas M, Madamanchi C, Brandes RP, Krause KH, Humphries J, Smith A, Burnand KG, and Runge MS. Nox activator 1: A potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 121: 549-559, 2010
121. O'Donnell VB, Tew DG, Jones OTG, and England PJ. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 290: 41-49, 1993
122. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, and Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci USA 94: 14483-14488, 1997
123. Pagano PJ, Ito Y, Tornheim K, Gallop PM, Tauber AI, and Cohen RA. An NADPH oxidase superoxide-generating system in the rabbit aorta. Am J Physiol 268: H2274-H2280, 1995
124. Paravicini TM and Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: Clinical implications and therapeutic possibilities. Diabetes Care 31(Suppl 2): S170-S180, 2008
125. Parnham M and Sies H. Ebselen: Prospective therapy for cerebral ischaemia. Expert Opin Investig Drugs 9: 607-619, 2000
126. Patel VB, Wang Z, Fan D, Zhabyeyev P, Basu R, Das SK, Wang W, Desaulniers J, Holland SM, Kassiri Z, and Oudit GY. Loss of p47phox subunit enhances susceptibility to biomechanical stress and heart failure because of dysregulation of cortactin and actin filaments. Circ Res 112: 1542-1556, 2013
127. Perry BN, Govindarajan B, Bhandarkar SS, Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont D, Losken A, Williams J, Brown LF, Tan X, Ioffe E, Yancopoulos GD, and Arbiser JL. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 126: 2316-2322, 2006
128. Petronio MS, Zeraik ML, Fonseca LM, and Ximenes VF. Apocynin: Chemical and biophysical properties of a NADPH oxidase inhibitor. Molecules 18: 2821-2839, 2013
129. Poli G, Leonarduzzi G, Biasi F, and Chiarpotto E. Oxidative stress and cell signalling. Curr Med Chem 11: 1163-1182, 2004
130. Pongnimitprasert N, El-Benna J, Foglietti MJ, Gougerot-Pocidalo MA, Bernard M, and Braut-Boucher F. Potential role of the "NADPH oxidases" (NOX/DUOX) family in cystic fibrosis. Ann Biol Clin (Paris) 66: 621-629, 2008
131. Quinn MT and Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: Comparison with nonphagocyte oxidases. J Leukoc Biol 76: 760-781, 2004
132. Radermacher KA, Wingler K, Langhauser F, Altenhofer S, Kleikers P, Hermans JJ, Hrabe De Angelis M, Kleinschnitz C, and Schmidt HH. Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal 18: 1418-1427, 2013
133. Ray PD, Huang BW, and Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 24: 981-990, 2012
134. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 89: 408-414, 2001
135. Rey FE, Li XC, Carretero OA, Garvin JL, and Pagano PJ. Perivascular superoxide anion contributes to impairment of endothelium-dependent relaxation. Role of gp91 phox. Circulation 106: 2497-2502, 2002
136. Rotrosen D, Kleinberg ME, Nunoi H, Leto T, Gallin JI, and Malech HL. Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem 265: 8745-8750, 1990
137. Schildknecht S, Weber A, Gerding HR, Pape R, Robotta M, Drescher M, Marquardt A, Daiber A, Ferger B, and Leist M. The NOX1/4 inhibitor GKT136901 as selective and direct scavenger of peroxynitrite. Curr Med Chem 2013 [Epub ahead of print]; DOI: 10.2174/09298673113209990179
138. Schramm A, Matusik P, Osmenda G, and Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol 56: 216-231, 2012
139. Schroder K. Isoform specific functions of Nox protein-derived reactive oxygen species in the vasculature. Curr Opin Pharmacol 10: 122-126, 2010
140. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, and Hebert RL. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299: F1348-F1358, 2010
141. Segal AW and Jones OT. Novel cytochrome b system in phagocytic vacuoles of human granulocytes. Nature 276: 515-517, 1978
142. Serrander L, Jaquet V, Bedard K, Plastre O, Hartley O, Arnaudeau S, Demaurex N, Schlegel W, and Krause KH. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 89: 1159-1167, 2007
143. Shi J, Ross CR, Leto TL, and Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox Proc Natl Acad Sci USA 93: 6014-6018, 1996
144. Shin YS, Song SJ, Kang SU, Hwang HS, Choi JW, Lee BH, Jung YS, and Kim CH. A novel synthetic compound, 3-Amino-3-(4-fluoro-phenyl)-1H-quinoline-2,4- dione, inhibits cisplatin-induced hearing loss by the suppression of reactive oxygen species: In vitro and in vivo study. Neuroscience 232C: 1-12, 2012
145. Sies H. Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic Biol Med 14: 313-323, 1993
146. Simons JM, T Hart BA, Ip Vai Ching TRAM, van Dijk H, and Labadie RP. Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils. Free Radic Biol Med 8: 251-258, 1990
147. Smith SM, Min J, Ganesh T, Diebold B, Kawahara T, Zhu Y, McCoy J, Sun A, Snyder JP, Fu H, Du Y, Lewis I, and Lambeth JD. Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits. Chem Biol 19: 752-763, 2012
148. Sorce S and Krause KH. NOX enzymes in the central nervous system: From signaling to disease. Antioxid Redox Signal 11: 2481-2504, 2009
149. Sorescu D, Weiss D, Lassšgue B, Clempus RE, Sz"ö cs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, and Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429-1435, 2002
150. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, and Morawietz H. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 344: 200-205, 2006
151. Sukumar P, Viswambharan H, Imrie H, Cubbon RM, Yuldasheva N, Gage M, Galloway S, Skromna A, Kandavelu P, Santos CX, Gatenby VK, Smith J, Beech DJ, Wheatcroft SB, Channon KM, Shah AM, and Kearney MT. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 62: 2130-2134, 2013
152. Sumimoto H. Structure, regulation and evolution of Noxfamily NADPH oxidases that produce reactive oxygen species. FEBS J 275: 3249-3277, 2008
153. Sun Q-A, Hess DT, Wang B, Miyagi M, and Stamler JS. Offtarget thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3- Triazolo[4,5-d]pyrimidine (VAS2870). Free Radic Biol Med 52: 1897-1902, 2012
154. Surace MJ and Block ML. Targeting microglia-mediated neurotoxicity: The potential of NOX2 inhibitors. Cell Mol Life Sci 69: 2409-2427, 2012
155. t Hart BA, Simons JM, Knaan-Shanzer S, Bakker NP, and Labadie RP. Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. Free Radic Biol Med 9: 127-131, 1990
156. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer H, and Rosenkranz S. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71: 331-341, 2006
157. Teng L, Fan LM, Meijles D, and Li JM. Divergent effects of p47(phox) phosphorylation at S303-S304 or S379 on tumor necrosis factor-Alpha signaling via TRAF4 and MAPK in endothelial cells. Arterioscler Thromb Vasc Biol 32: 1488-1496, 2012
158. Thakur S, Du J, Hourani S, Ledent C, and Li JM. Inactivation of adenosine A2A receptor attenuates basal and angiotensin II-induced ROS production by Nox2 in endothelial cells. J Biol Chem 285: 40104-40113, 2010
159. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: What is the clinical significance?. Hypertension 44: 248-252, 2004
160. Touyz RM and Briones AM. Reactive oxygen species and vascular biology: Implications in human hypertension. Hypertens Res 34: 5-14, 2011
161. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, and Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-Type NAD(P)H oxidase in smooth muscle cells from human resistance arteries. Regulation by angiotensin II. Circ Res 90: 1205-1213, 2002
162. Traber MG and Stevens JF. Vitamins C and E: Beneficial effects from a mechanistic perspective. Free Radic Biol Med 51: 1000-1013, 2011
163. Ueno N, Takeya R, Miyano K, Kikuchi H, and Sumimoto H. The NADPH oxidase Nox3 constitutively produces superoxide in a p22phox-dependentmanner: Its regulation by oxidase organizers and activators. J Biol Chem 280: 23328-23339, 2005
164. Valencia A, Sapp E, Kimm JS, McClory H, Reeves PB, Alexander J, Ansong KA, Masso N, Frosch MP, Kegel KB, Li X, and Difiglia M. Elevated NADPH oxidase activity contributes to oxidative stress and cell death in Huntington's disease. Hum Mol Genet 22: 1112-1131, 2013
165. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39: 44-84, 2007
166. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, and Gukovskaya AS. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 279: 34643-34654, 2004
167. Vara D, Campanella M, and Pula G. The novel NOX inhibitor 2-Acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner. Br J Pharmacol 168: 212-224, 2013
168. Vendrov AE, Madamanchi NR, Niu XL, Molnar KC, Runge M, Szyndralewiez C, Page P, and Runge MS. NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-Treated vascular smooth muscle cells and in atherosclerosis. J Biol Chem 285: 26545-26557, 2010
169. Verdine GL and Hilinski GJ. Stapled peptides for intracellular drug targets. Methods Enzymol 503: 3-33, 2012
170. Walch L, Massade L, Dufilho M, Brunet A, and Rendu F. Pro-Atherogenic effect of interleukin-4 in endothelial cells: Modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 187: 285-291, 2006
171. Wang Q, Zhou H, Gao H, Chen SH, Chu CH, Wilson B, and Hong JS. Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase. J Neuroinflammation 9: 32, 2012
172. Waris G and Ahsan H. Reactive oxygen species: Role in the development of cancer and various chronic conditions. J Carcinog 5: 14, 2006
173. Weaver M, Liu J, Pimentel D, Reddy DJ, Harding P, Peterson EL, and Pagano PJ. Adventitial delivery of dominant-negative p67phox attenuates neointimal hyperplasia of the rat carotid artery. Am J Physiol Heart Circ Physiol 290: H1933-H1941, 2006
174. Wiesel P, Hovsepian L, Mutch PJ, Herve J, Heitz F, and Page P. Safety and pharmacokinetics of single and multiple doses of a first in class dual NADPH oxidase 1 and 4 inhibitor administered orally in healthy subjects. In: Kidney Week 2012, edited by Nephrology ASo. San Diego, CA: Journal of the American Society of Nephrology; 2012. pp. 559A (Abstract FR-PO831
175. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, and Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885-898, 2010
176. Winterbourn CC and Hampton MB. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med 45: 549-561, 2008
177. Xu S, Jiang B, Hou X, Shi C, Bachschmid MM, Zang M, Verbeuren TJ, and Cohen RA. High-fat diet increases and the polyphenol, S17834, decreases acetylation of the sirtuin-1-dependent lysine-382 on p53 and apoptotic signaling in atherosclerotic lesion-prone aortic endothelium of normal mice. J Cardiovasc Pharmacol 58: 263-271, 2011
178. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, and Cohen RA. Polyphenols stimulate AMP-Activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55: 2180-2191, 2006
179. Zhang M, Perino A, Ghigo A, Hirsch E, and Shah AM. NADPH oxidases in heart failure: Poachers or gamekeepers?. Antioxid Redox Signal 18: 1024-1041, 2013
180. Zima AV and Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 71: 310-321, 2006